S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.37 (-4.16%)
MSFT   227.74 (-1.67%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   560.98 (-6.18%)
AMZN   2,954.79 (-1.52%)
NVDA   463.52 (-7.01%)
BABA   226.50 (-3.16%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.08 (-7.95%)
AMD   74.10 (-5.63%)
T   30.01 (+1.32%)
F   12.66 (+3.18%)
ACB   9.60 (+0.00%)
DIS   202.54 (+6.61%)
BA   224.40 (+0.53%)
NFLX   493.38 (-4.46%)
PFE   34.34 (-0.15%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.37 (-4.16%)
MSFT   227.74 (-1.67%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   560.98 (-6.18%)
AMZN   2,954.79 (-1.52%)
NVDA   463.52 (-7.01%)
BABA   226.50 (-3.16%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.08 (-7.95%)
AMD   74.10 (-5.63%)
T   30.01 (+1.32%)
F   12.66 (+3.18%)
ACB   9.60 (+0.00%)
DIS   202.54 (+6.61%)
BA   224.40 (+0.53%)
NFLX   493.38 (-4.46%)
PFE   34.34 (-0.15%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.37 (-4.16%)
MSFT   227.74 (-1.67%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   560.98 (-6.18%)
AMZN   2,954.79 (-1.52%)
NVDA   463.52 (-7.01%)
BABA   226.50 (-3.16%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.08 (-7.95%)
AMD   74.10 (-5.63%)
T   30.01 (+1.32%)
F   12.66 (+3.18%)
ACB   9.60 (+0.00%)
DIS   202.54 (+6.61%)
BA   224.40 (+0.53%)
NFLX   493.38 (-4.46%)
PFE   34.34 (-0.15%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   300.30 (-2.71%)
AAPL   116.37 (-4.16%)
MSFT   227.74 (-1.67%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   560.98 (-6.18%)
AMZN   2,954.79 (-1.52%)
NVDA   463.52 (-7.01%)
BABA   226.50 (-3.16%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.08 (-7.95%)
AMD   74.10 (-5.63%)
T   30.01 (+1.32%)
F   12.66 (+3.18%)
ACB   9.60 (+0.00%)
DIS   202.54 (+6.61%)
BA   224.40 (+0.53%)
NFLX   493.38 (-4.46%)
PFE   34.34 (-0.15%)
Log in
NASDAQ:JAZZ

Jazz Pharmaceuticals Stock Forecast, Price & News

$161.34
-3.41 (-2.07 %)
(As of 03/8/2021 03:59 PM ET)
Add
Compare
Today's Range
$161.02
Now: $161.34
$167.18
50-Day Range
$150.19
MA: $163.81
$173.50
52-Week Range
$86.88
Now: $161.34
$178.64
Volume24,382 shs
Average Volume834,916 shs
Market Capitalization$9.09 billion
P/E Ratio50.90
Dividend YieldN/A
Beta1.08
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals logo

Headlines

Recap: Jazz Pharmaceuticals Q4 Earnings
February 24, 2021 |  finance.yahoo.com
Is Now The Time to Buy Jazz Pharmaceuticals Stock?
February 5, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone011-353-1634-7800
Employees1,940
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$21.98 per share
Book Value$54.99 per share

Profitability

Net Income$523.37 million

Miscellaneous

Market Cap$9.09 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

48th out of 1,971 stocks

Pharmaceutical Preparations Industry

19th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$161.34
-3.41 (-2.07 %)
(As of 03/8/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

Is Jazz Pharmaceuticals a buy right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Jazz Pharmaceuticals?

Wall Street analysts have given Jazz Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jazz Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 4,120,000 shares, an increase of 30.0% from the January 28th total of 3,170,000 shares. Based on an average trading volume of 691,300 shares, the short-interest ratio is presently 6.0 days. Approximately 7.6% of the company's stock are short sold.
View Jazz Pharmaceuticals' Short Interest
.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Jazz Pharmaceuticals
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, February, 23rd. The specialty pharmaceutical company reported $4.00 EPS for the quarter, topping the Zacks' consensus estimate of $3.58 by $0.42. The specialty pharmaceutical company had revenue of $665.52 million for the quarter, compared to analyst estimates of $639.83 million. Jazz Pharmaceuticals had a net margin of 7.86% and a trailing twelve-month return on equity of 20.16%. The company's revenue was up 14.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.42 earnings per share.
View Jazz Pharmaceuticals' earnings history
.

How has Jazz Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Jazz Pharmaceuticals' stock was trading at $108.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, JAZZ stock has increased by 49.3% and is now trading at $161.34.
View which stocks have been most impacted by COVID-19
.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2021 After-Hours earnings guidance on Tuesday, February, 23rd. The company provided EPS guidance of 15.65-16.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.78. The company issued revenue guidance of $2.55-2.7 billion, compared to the consensus revenue estimate of $2.56 billion.

What price target have analysts set for JAZZ?

18 Wall Street analysts have issued 1-year price objectives for Jazz Pharmaceuticals' stock. Their forecasts range from $128.00 to $233.00. On average, they expect Jazz Pharmaceuticals' stock price to reach $184.00 in the next twelve months. This suggests a possible upside of 14.0% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:
  • Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 57, Pay $2.33M)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 58, Pay $1.24M)
  • Ms. Neena M. Patil J.D., Sr. VP & Gen. Counsel (Age 46, Pay $331.61k)
  • Dr. Robert Iannone M.D., Exec. VP of R&D and Chief Medical Officer (Age 53, Pay $771.48k)
  • Ms. Renee D. Gala, Exec. VP & CFO (Age 48)
  • Ms. Patricia Carr, VP of Fin. & Principal Accounting Officer (Age 50)
  • Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 63)
  • Ms. Andrea N. Flynn, VP & Head of Investor Relations
  • Mr. George Eliades Ph.D., Sr. VP of Corp. Devel. & Chief Transformation Officer
  • Ms. Heidi Manna, Sr. VP & Chief HR Officer

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jazz Pharmaceuticals' key competitors?

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.48%), Renaissance Technologies LLC (5.56%), Boston Partners (1.75%), Dimensional Fund Advisors LP (1.59%), Dimensional Fund Advisors LP (1.57%) and Janus Henderson Group PLC (1.56%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Catherine A Sohn, Finbar Larkin, Kenneth W O'keefe, Michael Patrick Miller, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals
.

Which major investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Davidson Kempner Capital Management LP, Renaissance Technologies LLC, AJO LP, Price T Rowe Associates Inc. MD, Alyeska Investment Group L.P., Alyeska Investment Group L.P., and First Trust Advisors LP. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Finbar Larkin, Michael Patrick Miller, Patricia Carr, Patrick G Enright, and Paul L Berns.
View insider buying and selling activity for Jazz Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including SummerHaven Investment Management LLC, Norges Bank, BlackRock Inc., Jennison Associates LLC, Asymmetry Capital Management L.P., Morgan Stanley, Panagora Asset Management Inc., and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for Jazz Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $161.34.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals has a market capitalization of $9.09 billion and generates $2.16 billion in revenue each year. The specialty pharmaceutical company earns $523.37 million in net income (profit) each year or $14.60 on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 1,940 workers across the globe.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

Where are Jazz Pharmaceuticals' headquarters?

Jazz Pharmaceuticals is headquartered at FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.